Literature DB >> 9075852

Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing.

D P Turner1, M Zuckerman, G J Alexander, J Waite, T Wreghitt.   

Abstract

BACKGROUND: Hepatitis B virus infection originating from hepatitis B surface antigen-negative, hepatitis B core antibody (anti-HBc)-positive organ donors has been documented, and anti-HBc-positive donors have been excluded as liver donors. We assessed the prevalence of anti-HBc in UK organ donors and followed up recipients of organs from anti-HBc-positive donors for serological evidence of posttransplantation hepatitis B virus infection.
METHODS: Serum samples from 400 hepatitis B surface antigen-negative organ donors were tested for anti-HBc.
RESULTS: Only five (1.25%) of 20 sera in which anti-HBc was initially detected were confirmed as anti-HBc positive on further testing. Posttransplantation serum samples from four recipients of confirmed anti-HBc-positive organs showed no evidence of de novo hepatitis B infection.
CONCLUSIONS: The poor specificity of some anti-HBc immunoassays was confirmed and suggests that donor exclusion on the basis of a single anti-HBc-positive result may result in the inappropriate loss of organs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9075852     DOI: 10.1097/00007890-199703150-00026

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  1 in total

1.  Screening for hepatitis B virus DNA in serum of organ donors and renal transplant recipients.

Authors:  M Miédougé; L Rostaing; J M Mansuy; K Sandres-Sauné; F Boudet; J Izopet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-25       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.